Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.75 |
| ▸ | TTR | P02766 | 2/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.75 |
| ▸ | MEN1 | O00255 | 1/20 | 0.75 |
| ▸ | USP2 | O75604 | 1/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.75 |
| ▸ | DHFR | P00374 | 1/20 | 0.75 |
| ▸ | CA1 | P00915 | 1/20 | 0.75 |
| ▸ | CA2 | P00918 | 1/20 | 0.75 |
| ▸ | LMNA | P02545 | 1/20 | 0.75 |
| ▸ | ALB | P02768 | 1/20 | 0.75 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.75 |
| ▸ | HPGD | P15428 | 1/20 | 0.75 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.75 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.75 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.75 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.75 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30590997 | 1.00 | ACMSD (0.75) | ACMSDTTRKDM4EMEN1USP2 | |
| Diflunisal SCHEMBL4337 | 0.86 | ACMSD (1.00) | ACMSDTTRKDM4EMEN1USP2 | |
| Diflunisal SCHEMBL3848363 | 0.86 | ACMSD (1.00) | ACMSDTTRKDM4EMEN1USP2 | |
| Diflunisal SCHEMBL30509654 | 0.86 | ACMSD (1.00) | ACMSDTTRKDM4EMEN1USP2 | |
| Diflunisal SCHEMBL29367380 | 0.86 | ACMSD (1.00) | ACMSDTTRKDM4EMEN1USP2 | |
| SCHEMBL12608936 | 0.84 | ACMSD (0.75) | ACMSDTTRKDM4EMEN1USP2 | |
| Diflunisal SCHEMBL11425421 | 0.84 | ACMSD (0.97) | ACMSDTTRKDM4EMEN1USP2 | |
| Diflunisal SCHEMBL20876816 | 0.84 | ACMSD (0.97) | ACMSDTTRKDM4EMEN1USP2 | |
| Diflunisal SCHEMBL1869144 | 0.84 | ACMSD (0.97) | ACMSDTTRKDM4EMEN1USP2 | |
| Diflunisal SCHEMBL28916416 | 0.84 | ACMSD (0.97) | ACMSDTTRKDM4EMEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099491-A1 | PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASES WITH HIGH PENETRATION PRODRUGS OF ASPIRIN AND OTHER NSAIDS | TECHFIELDS INC. (JP) | 2025-03-27 | — | — | US | disclosed |
| US-20230219886-A1 | NOVEL SELENO-NSAID ANALOGS AND USES THEREOF | THE PENN STATE RESEARCH FOUNDATION | 2023-07-13 | — | — | US | disclosed |
| US-9162993-B2 | Preparation and pharmaceuticals of biphenyl benzamide-derived derivatives | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2015-10-20 | — | — | US | disclosed |
| US-20150191438-A1 | PREPARATION AND PHARMACEUTICALS OF BIPHENYL BENZAMIDE-DERIVED DERIVATIVES | NATIONAL DEFENSE MEDICAL UNIVERSITY (TW) | 2015-07-09 | — | — | US | disclosed |
| US-8975255-B2 | Preparation and pharmaceuticals of biphenyl benzamide-derived derivatives | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2015-03-10 | — | — | US | disclosed |
| US-20130281444-A1 | PREPARATION AND PHARMACEUTICALS OF BIPHENYL BENZAMIDE-DERIVED DERIVATIVES | NATIONAL DEFENSE MEDICAL UNIVERSITY (TW) | 2013-10-24 | — | — | US | disclosed |
| US-4329363-A | Substituted mercapto acid amides and their use | MERCK & CO., INC. (US) | 1982-05-11 | — | — | US | disclosed |
| US-4216160-A | IMMUNOREGULANTS FOR CORRECTING AN INBALANCE OF IMMUNE HOMEOSTASIS | MERCK & CO., INC. (US) | 1980-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191438-A1 | PREPARATION AND PHARMACEUTICALS OF BIPHENYL BENZAMIDE-DERIVED DERIVATIVES | CYP2B6, UGT2B7, CYP3A5 | ACMSD 1719/4885TTR 866/4885KDM4E 587/4885 |
| US-20250099491-A1 | PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASES WITH HIGH PENETRATION PRODRUGS OF ASPIRIN AND OTHER NSAIDS | PTGS1, PTGIS, PTGS2 | ACMSD 13/4885TTR 995/4885KDM4E 3183/4885 |
| US-20130281444-A1 | PREPARATION AND PHARMACEUTICALS OF BIPHENYL BENZAMIDE-DERIVED DERIVATIVES | CYP2B6, UGT2B7, CYP3A5 | ACMSD 1658/4885TTR 944/4885KDM4E 547/4885 |
| US-20230219886-A1 | NOVEL SELENO-NSAID ANALOGS AND USES THEREOF | SELENOI, SCLY, GPX1 | ACMSD 3412/4885TTR 793/4885KDM4E 4047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.